Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T3011 + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- ImmVira
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
This combination involves **MVR-T3011**, an oncolytic virus product developed by ImmVira Pharma Co. Ltd., and **pembrolizumab**, a checkpoint inhibitor. MVR-T3011 is administered intratumorally and is being studied for its ability to modify the tumor microenvironment and enhance immune response. Pembrolizumab is an anti-PD-1 antibody that promotes immune response against cancer cells. The combination is being evaluated for safety and efficacy in treating advanced or metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC).
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on T3011 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T3011 + pembrolizumab.